Enovis Corporation (ENOV) Stock
NYSE · ENOV
18.19
Fundamentals
Market cap
$1.06B
Price / Earnings ratio
-1.0x
Price / Sales ratio
0.5x
Price / Book ratio
0.7x
Return on assets
-27.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

The Motley Fool
Insider at Medical Device Maker Buys More Than 7,500 Shares
NeutralENOVSeptember 14, 2026
The Motley FoolNeutral
Insider at Medical Device Maker Buys More Than 7,500 Shares
ENOV

Zacks Investment Research
What Makes Enovis (ENOV) a New Buy Stock
NeutralENOVSeptember 3, 2026
Zacks Investment ResearchNeutral
What Makes Enovis (ENOV) a New Buy Stock
ENOV

Zacks Investment Research
Enovis (ENOV) Loses 33% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
NeutralENOVSeptember 3, 2026
Zacks Investment ResearchNeutral
Enovis (ENOV) Loses 33% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
ENOV

Zacks Investment Research
Enovis Boosts Surgical Robotics Portfolio With eCential Acquisition
NeutralENOVSeptember 2, 2026
Zacks Investment ResearchNeutral
Enovis Boosts Surgical Robotics Portfolio With eCential Acquisition
ENOV
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy8
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
3B2B890M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
5B3B2B0
Revenue to Profit
2025$2.2B
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-1.2B
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

The Motley Fool
Insider at Medical Device Maker Buys More Than 7,500 Shares
NeutralENOVSeptember 14, 2026
The Motley FoolNeutral
Insider at Medical Device Maker Buys More Than 7,500 Shares
ENOV

Zacks Investment Research
What Makes Enovis (ENOV) a New Buy Stock
NeutralENOVSeptember 3, 2026
Zacks Investment ResearchNeutral
What Makes Enovis (ENOV) a New Buy Stock
ENOV

Zacks Investment Research
Enovis (ENOV) Loses 33% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
NeutralENOVSeptember 3, 2026
Zacks Investment ResearchNeutral
Enovis (ENOV) Loses 33% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
ENOV

Zacks Investment Research
Enovis Boosts Surgical Robotics Portfolio With eCential Acquisition
NeutralENOVSeptember 2, 2026
Zacks Investment ResearchNeutral
Enovis Boosts Surgical Robotics Portfolio With eCential Acquisition
ENOV

MarketBeat
Enovis Targets Robotic Surgery Expansion With €155M eCential Robotics Deal
NeutralENOVSeptember 1, 2026
MarketBeatNeutral
Enovis Targets Robotic Surgery Expansion With €155M eCential Robotics Deal
ENOV

MarketBeat
Enovis Q2 Earnings Call Highlights
NeutralENOVAugust 8, 2026
MarketBeatNeutral
Enovis Q2 Earnings Call Highlights
ENOV

Zacks Investment Research
Enovis (ENOV) Beats Q2 Earnings and Revenue Estimates
NeutralENOVAugust 6, 2026
Zacks Investment ResearchNeutral
Enovis (ENOV) Beats Q2 Earnings and Revenue Estimates
ENOV

Zacks Investment Research
Does Enovis (ENOV) Have the Potential to Rally 65.45% as Wall Street Analysts Expect?
NeutralENOVMay 13, 2026
Zacks Investment ResearchNeutral
Does Enovis (ENOV) Have the Potential to Rally 65.45% as Wall Street Analysts Expect?
ENOV

MarketBeat
Enovis Q1 Earnings Call Highlights
NeutralENOVMay 10, 2026
MarketBeatNeutral
Enovis Q1 Earnings Call Highlights
ENOV

Zacks Investment Research
Enovis (ENOV) Q1 Earnings and Revenues Beat Estimates
NeutralENOVMay 7, 2026
Zacks Investment ResearchNeutral
Enovis (ENOV) Q1 Earnings and Revenues Beat Estimates
ENOV
About Enovis Corporation
No description available.
SectorHealthcare
IndustryMedical Devices
Employees7,802
CEOMr. Damien McDonald
IPO DateMay 8, 2008
HeadquartersLewisville, TX
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Damien McDonald | CEO & Director | 1965 |
| Mr. Phillip Benjamin Berry | Senior VP & CFO | 1979 |
| Ms. Patricia A. Lang | Advisor | 1959 |
| Mr. Terry D. Ross | Group President Prevention & Recovery | 1970 |
| Mr. Louie Vogt | Group President of Reconstructive | 1981 |
| Mr. John Kleckner | VP, Controller & Chief Accounting Officer | 1977 |
| Mr. Oliver Engert | Chief Administrative Officer | 1965 |
| Mr. Kyle William Rose | Vice President of Investor Relations | — |
| Mr. Bradley J. Tandy J.D. | Senior VP & Chief Legal Officer | 1959 |
| Ms. Laura Singleton | Senior VP & Chief Human Resources Officer | — |
Fundamentals
Valuation
Market cap$1.06B
Price-to-sales ratio0.46
Price-to-book value0.71
Price-earnings ratio-1.00
Return on Equity-60.00%
Return on Sales-47.00%
Return on Assets-27.00%
PEG ratio1.90
Earnings Per Share
Earnings Per Share$-19.27
Income Statement
Average volume1,981,806
EBITDA$-773.03M
1 year high (52w)$34.28
1 year low (52w)$17.30
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
8 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$38.63
Est return
109.24%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | -7.9 | +1.9 | -17.6 | +6.6 | -15.1 | -7.1 | +4.0 | +9.2 | -5.3 | |||
| 2023 | +15.7 | -10.6 | -6.7 | +8.9 | -10.2 | +19.2 | +1.1 | -12.1 | -6.7 | -10.3 | +9.8 | +9.9 |
| 2024 | +5.9 | +0.3 | +3.4 | -10.1 | -9.3 | -8.1 | +7.4 | +0.1 | -3.4 | -0.5 | +15.0 | -11.0 |
| 2025 | +6.0 | -14.6 | +0.9 | -7.0 | -9.5 | +5.8 | -18.8 | +20.0 | -1.6 | +2.6 | -3.5 | -9.3 |
| 2026 | -16.9 | +14.9 | -11.5 | +0.3 | -4.0 | -4.6 | +45.5 | -21.7 | -10.1 |



